Karyopharm Therapeutics Inc. (KPTI) Options Positioning, Max Pain & Unusual Sweeps

KPTI scores 31 out of 100 for an E grade, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 9 / 20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5 / 20 (institutional accumulation and options positioning), Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). Every pillar sits well below half its maximum, with the weakest readings in insider conviction and institutional flow. For a prospective investor, the upside case rests on an unusually large gap between the current price and the 52-week high, but the score pattern indicates that the fundamental cash engine and insider signals do not currently support that case. The valuation tradeoff is that a $0.88 price against a $20.0M market cap, paired with negative operating and net margins, leaves little cushion if reported losses persist. The second-order implication is that cash reserves and financing needs, rather than revenue growth, will likely drive the outcome. This is an analytical summary of the source data, not personalized financial advice.

Karyopharm Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The FY 2025 SEC financials report revenue of $146.1M, indicating ongoing commercial or collaboration revenue, but the source does not identify its source.

Revenue has been essentially flat across the three periods while operating losses persisted in each. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. The Roarable RQD rating reports an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and Debt/Equity of 0.5. The FY 2025 cash balance of $60.5M is reported against a FY 2025 free cash flow of -$75.

• 🐂 Primary Bull Case: The stock trades at $0.88 after a 52-week range of $0.31 to $10.99 and reported a 5.73% gain, with $60.5M in cash against a $20.0M market cap. With Fundamental Cash Engine at 9/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $0.31 – $10.99 52-week range.
• 🐻 Primary Bear Case: Operating margin is -60%, ROIC is -35%, FCF yield is 0%, and FY 2025 net loss of -$196.0M sits against a Piotroski F-Score of 2/9 and an RQD score of 31 (E). Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

The source data therefore identifies no upstream suppliers, downstream customers, or sector correlations beyond the broad Health Care classification. A prospective investor should watch for any second-order effects of the planned Ayrmid merger on financing and cash runway, given the reported FY 2025 free cash flow of -$75.4M. Because beta is 1.0, the source does not indicate how the stock would respond to sector-wide moves beyond that market-sensitivity figure.

• Key Question #1: What are the terms and expected timeline of the planned merger with Ayrmid Ltd., and how would they affect shareholders?
• Key Question #2: What drove the 12% price increase referenced in the kalkine.ca item, given that no news was identified?
• Key Question #3: What is the company's debt position, since debt is listed as N/A despite a Debt/Equity ratio of 0.5?